{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ma J"],"funding":["NCI NIH HHS"],"pagination":["578-88"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC2729124"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["15(2)"],"pubmed_abstract":["<h4>Purpose</h4>Antiangiogenic drug treatment inhibits tumor growth by decreasing blood supply, which can also reduce the delivery of other therapeutic agents. Presently, we investigated the effect of the vascular endothelial growth factor receptor tyrosine kinase inhibitor axitinib (AG-013736) on tumor vascular patency and chemotherapeutic drug uptake. Furthermore, the effect of axitinib on the antitumor activity of combination treatments with cyclophosphamide was examined.<h4>Experimental design</h4>Prostate cancer PC-3 xenografts were used to evaluate the effect of axitinib treatment on tumor vascular morphology, fluorescent dye perfusion, hypoxia, and uptake of 4-hydroxycyclophosphamide, the active metabolite of the chemotherapeutic prodrug cyclophosphamide. Sequential or simultaneous "],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["Dominant effect of antiangiogenesis in combination therapy involving cyclophosphamide and axitinib."],"pmcid":["PMC2729124"],"funding_grant_id":["CA49248","R01 CA049248","R01 CA049248-19"],"pubmed_authors":["Waxman DJ","Ma J"],"additional_accession":[]},"is_claimable":false,"name":"Dominant effect of antiangiogenesis in combination therapy involving cyclophosphamide and axitinib.","description":"<h4>Purpose</h4>Antiangiogenic drug treatment inhibits tumor growth by decreasing blood supply, which can also reduce the delivery of other therapeutic agents. Presently, we investigated the effect of the vascular endothelial growth factor receptor tyrosine kinase inhibitor axitinib (AG-013736) on tumor vascular patency and chemotherapeutic drug uptake. Furthermore, the effect of axitinib on the antitumor activity of combination treatments with cyclophosphamide was examined.<h4>Experimental design</h4>Prostate cancer PC-3 xenografts were used to evaluate the effect of axitinib treatment on tumor vascular morphology, fluorescent dye perfusion, hypoxia, and uptake of 4-hydroxycyclophosphamide, the active metabolite of the chemotherapeutic prodrug cyclophosphamide. Sequential or simultaneous ","dates":{"release":"2009-01-01T00:00:00Z","publication":"2009 Jan","modification":"2026-03-16T16:53:30.513Z","creation":"2019-03-27T00:24:21Z"},"accession":"S-EPMC2729124","cross_references":{"pubmed":["19147763"],"doi":["10.1158/1078-0432.ccr-08-1174","10.1158/1078-0432.CCR-08-1174"]}}